Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer
Not Applicable
- Conditions
- Small-cell lung cancer
- Registration Number
- JPRN-UMIN000002618
- Lead Sponsor
- Tohoku University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. Severe co-morbidities 2. Symptomatic brain metastasis 3. Massive effusion that require drainage 4. Pregnant woman
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method